ORTHOCELL LIMITED (OCC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

OCC - ORTHOCELL LIMITED

Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.06
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.39

19 Jul
2024

0.010

OPEN

$0.38

2.63%

HIGH

$0.39

129,035

LOW

$0.38

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-3.2
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx4.2 M
Book Value Per Share xxxxxxxxxxxxxxx3.1
Net Operating Cash Flow xxxxxxxxxxxxxxx14.6 M
Net Profit Margin xxxxxxxxxxxxxxx-147.26 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-77.84 %
Return on Invested Capital xxxxxxxxxxxxxxx-74.28 %
Return on Assets xxxxxxxxxxxxxxx-18.51 %
Return on Equity xxxxxxxxxxxxxxx-77.84 %
Return on Total Capital xxxxxxxxxxxxxxx-120.42 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx14.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx25 M
Price To Book Value xxxxxxxxxxxxxxx11.23

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.6 M
Capex % of Sales xxxxxxxxxxxxxxx14.88 %
Cost of Goods Sold xxxxxxxxxxxxxxx1 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx13 M
Research & Development xxxxxxxxxxxxxxx8 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
EXPERT VIEWS
Display All Commentary

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Petra Capital

19/06/2024

1

Buy

$1.28

228.21%

Petra Capital believes the application for SmrtGraft in Australia by Orthocell could introduce a third revenue stream for the Celgro platform, enhancing its potential without much additional cost.

SmrtGraft is anticipated to be approved by June 2025 in Australia, the broker highlights, with a broader market applicability across multiple tendon repairs. A US market entry is expected a few years later.

Remplir, the company's nerve repair product, is on track for US approval by 1Q2025, with existing distribution synergies in place through Device Technologies.

No changes have been made to earnings forecasts. $1.28 target and Buy rating unchanged.

FORECAST
Petra Capital forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -4.00 cents.
Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -2.80 cents.

OCC STOCK CHART